Election of Vicente Anido, Jr. to NicOx SA's Board of Directors - Vaughn Kailian Re-Elected Director
Published: Jun 21, 2013
SOPHIA ANTIPOLIS CEDEX, FRANCE--(Marketwired - June 21, 2013) -
Election of Vicente Anido, Jr. to Nicox's Board of Directors
Vaughn Kailian re-elected Director
June 21, 2013.
Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX) today announced the election of Vicente Anido, Jr., PhD., to the Company's Board of Directors for a period of four years. Dr. Anido is a highly experienced and respected leader in the ophthalmology sector and most recently served as President and Chief Executive Officer of ISTA Pharmaceuticals prior to its acquisition by Bausch + Lomb. The Company also announced that Vaughn Kailian, Managing Director at MPM Capital and former President & CEO of COR Therapeutics, has been re-elected as a member of the Board of Directors for a period of four years. Bengt Samuelsson and Jorgen Buus Lassen have retired from the Board due to their reaching the age limit set out in the Company's by-laws. "I am honoured to join Nicox's Board of Directors. The Company already has a number of promising assets and a sound strategy to become an international and innovative ophthalmic company. I look forward to sharing my experience and contributing to the future growth of the business", said Vicente Anido. "We are pleased to welcome Vicente Anido as a member of the Nicox Board of Directors and would also like to thank Vaughn Kailian for his continued support for Nicox as a Board member" said Michele Garufi, Chief Executive Officer of Nicox. "We look forward to their unique contributions as we continue to transform Nicox into a leading international ophthalmology company." "On behalf of the Board, Nicox's management and its employees I would like to express my sincere gratitude to Bengt Samuelsson and Jorgen Buus Lassen. Their guidance and support has been of great value to the Company over the past fifteen years, particularly during our current period of transition."
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is creating a new mid-sized international player in the ophthalmic market by building a diversified portfolio of innovative therapies and diagnostic tools. With a heritage of scientific, business development and commercial expertise, the Nicox team is focused on developing and marketing novel pharmaceuticals and diagnostic devices that can help people to enhance their sight. In the United States, Nicox markets AdenoPlus(®), a test for the differential diagnosis of acute conjunctivitis in-licensed from RPS®.
The Company's pipeline includes latanoprostene bunod, a novel drug-candidate based on Nicox's proprietary nitric oxide (NO)-donating R&D platform, developed in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donating compounds are under development in non-ophthalmic indications, notably through partners, including Merck (known as MSD outside the United States and Canada).
Nicox S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Small Caps). For more information please visit www.nicox.com.
This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated in the forward-looking statements. Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the « Document de référence, rapport financier annuel et rapport de gestion 2012 » filed with the French Autorité des Marchés Financiers (AMF) on March 22, 2013 and available on Nicox's website (www.nicox.com) and on the AMF's website (www.amf-france.org).
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NICOX via Thomson Reuters ONE [HUG#1710980]
Gavin Spencer | Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00 | Email Contact
Media Relations FTI Consulting
Julia Phillips | D+44 (0)20 7269 7187 | M +44 (0) 7770 827 263
Stephanie Cuthbert | D +44 (0)20 3077 0458 | M +44 (0)
Mo Noonan | D +44 (0)20 7269 7116 | M +44 (0)7876 444 977
Drakkar 2 | Bât D | 2405 route des Dolines | CS 10313 | Sophia
06560 Valbonne | France
T: +33 (0)4 97 24 53 00 | F: +33 (0)4 97 24 53 99
Election of Vicente Anido, Jr. to Nicox's Board of Directors:
Help employers find you! Check out all the jobs and post your resume.